IRVINE, CA / ACCESSWIRE / May 4, 2023 / PRO-DEX, INC. (NASDAQ:PDEX) today announced financial results for its fiscal 2023 third quarter ended March 31, 2023. The Company also filed its Quarterly Report on Form 10-Q for the third quarter of fiscal year 2023 with the Securities and Exchange Commission today.
Quarter Ended March 31, 2023
Net sales for the three months ended March 31, 2023, increased $3.8 million, or 41%, to $13.1 million from $9.3 million for the three months ended March 31, 2022, due primarily to increased repair revenue of $3.2 million related to an enhanced repair program launched this fiscal year to upgrade the handpiece we sell our largest customer to its most current generation.
Gross profit for the three months ended March 31, 2023, increased $953,000, or 33%, to $3.8 million from $2.9 million for the same period in fiscal 2022. The gross profit increase is consistent with our increase in net sales and is benefited by our resolution and agreement with our largest customer related to previously upgraded repairs. Additionally, we have continued to experience higher costs across much of our supply chain.
Operating expenses (which include selling, general and administrative, and research and development expenses) for the quarter ended March 31, 2023, decreased slightly, by 5%, compared to the same period in fiscal 2022 mostly due to reduced general and administration expenses.
Net income for the quarter ended March 31, 2023, was $1.3 million, or $0.36 per diluted share, compared to $462,000, or $0.12 per diluted share, for the corresponding quarter in fiscal 2022.
Nine Months Ended March 31, 2023
Net sales for the nine months ended March 31, 2023, increased $6.0 million, or 20%, to $35.4 million from $29.4 million for the nine months ended March 31, 2022, due to increased repair revenue of $4.3 million related to the enhanced repair program described above, as well as an increase of $1.5 million in billable non-recurring engineering projects.
Gross profit for the nine months ended March 31, 2023, decreased $299,000, or 3%, compared to the same period in fiscal 2022. The gross profit decline for the nine months ended March 31, 2023, is due in part to the enhanced repair program described above, which includes the advance replacement of many costly components of the handpiece, as well as higher costs across much of our supply chain.
Operating expenses (which include selling, general and administrative, and research and development expenses) for the nine months ended March 31, 2023, decreased 9% to $5.2 million from $5.7 million in the prior fiscal year's corresponding period, mostly due to reduced non-cash stock based compensation expense recorded in general and administrative expenses.
Net income for the nine months ended March 31, 2023 was $3.3 million, or $0.89, per diluted share, compared to $2.5 million, or $0.65 per diluted share, for the corresponding period in fiscal 2022.
CEO Comments
"We are pleased with our third quarter results, as we continue to demonstrate our ability to grow revenue while controlling operating expenses," said the Company's President and Chief Executive Officer, Richard L. ("Rick") Van Kirk. "We are tracking toward another record fiscal year from a revenue perspective, and we expect to have completed the transfer of all of our assembly and repairs operations to the Franklin facility in the fourth quarter."
About Pro-Dex, Inc.
Pro-Dex, Inc. specializes in the design, development, and manufacture of autoclavable, battery-powered and electric, multi-function surgical drivers and shavers used primarily in the orthopedic, thoracic, and maxocranial facial markets. We have patented adoptive torque-limiting software and proprietary sealing solutions which appeal to our customers, primarily medical device distributors. Pro-Dex also manufactures and sells rotary air motors to a wide range of industries. Pro-Dex's products are found in hospitals and medical engineering labs around the world. For more information, visit the Company's website at www.pro-dex.com.
Statements herein concerning the Company's plans, growth, and strategies may include 'forward-looking statements' within the context of the federal securities laws. Statements regarding the Company's future events, developments, and future performance, (including, but not limited to, the anticipated commencement of operations at the Franklin facility and expected fiscal year revenue), as well as management's expectations, beliefs, plans, estimates, or projections relating to the future, are forward-looking statements within the meaning of these laws. The Company's actual results may differ materially from those suggested as a result of various factors. Interested parties should refer to the disclosure concerning the operational and business concerns of the Company set forth in the Company's filings with the Securities and Exchange Commission.
(tables follow)
PRO-DEX, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
(In thousands, except share amounts)
| March 31, 2023 | June 30, 2022 | |||||||
ASSETS | ||||||||
Current Assets: | ||||||||
Cash and cash equivalents............................................... | $ | 2,088 | $ | 849 | ||||
Investments.................................................................... | 1,149 | 755 | ||||||
Accounts receivable, net of allowance for doubtful accounts of $2 and $0 at March 31, 2023 and at June 30, 2022, respectively................................................. | 10,565 | 15,384 | ||||||
Deferred costs............................................................... | 279 | 710 | ||||||
Inventory....................................................................... | 15,145 | 12,678 | ||||||
Prepaid expenses and other current assets........................ | 1,919 | 790 | ||||||
Total current assets..................................................... | 31,145 | 31,166 | ||||||
Land and building, net........................................................ | 6,273 | 6,343 | ||||||
Equipment and leasehold improvements, net........................ | 5,162 | 4,833 | ||||||
Right of use asset, net......................................................... | 1,968 | 2,248 | ||||||
Intangibles, net.................................................................. | 87 | 118 | ||||||
Deferred income taxes, net................................................. | 764 | 797 | ||||||
Investments....................................................................... | 1,534 | 1,779 | ||||||
Other assets....................................................................... | 42 | 42 | ||||||
Total assets.................................................................... | $ | 46,975 | $ | 47,326 | ||||
LIABILITIES AND SHAREHOLDERS' EQUITY | ||||||||
Current Liabilities: | ||||||||
Accounts payable........................................................... | $ | 3,068 | $ | 3,761 | ||||
Accrued expenses........................................................... | 2,425 | 2,751 | ||||||
Deferred revenue............................................................ | 57 | 1,013 | ||||||
Income taxes payable...................................................... | 1,480 | 544 | ||||||
Note payable.................................................................. | 3,114 | 3,285 | ||||||
Total current liabilities................................................ | 10,144 | 11,354 | ||||||
Lease liability, net of current portion.................................. | 1,745 | 2,054 | ||||||
Notes payable, net of current portion.................................. | 9,247 | 10,250 | ||||||
Total non-current liabilities......................................... | 10,992 | 12,304 | ||||||
Total liabilities............................................................... | 21,136 | 23,658 | ||||||
Shareholders' equity: | ||||||||
Common shares; no par value; 50,000,000 shares authorized; 3,545,309 and 3,596,131 shares issued and outstanding at March 31, 2023 and June 30, 2022, respectively................................................................ | 6,585 | 7,682 | ||||||
Retained earnings .......................................................... | 19,254 | 15,986 | ||||||
Total shareholders' equity........................................... | 25,839 | 23,668 | ||||||
Total liabilities and shareholders' equity................... | $ | 46,975 | $ | 47,326 | ||||
PRO-DEX, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED INCOME STATEMENTS
(Unaudited)
(In thousands, except per share amounts)
| Three Months Ended March 31, | Nine Months Ended March 31, | |||||||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||||||
Net sales................................................................. | $ | 13,079 | $ | 9,265 | $ | 35,448 | $ | 29,426 | ||||||||
Cost of sales .......................................................... | 9,268 | 6,407 | 26,058 | 19,737 | ||||||||||||
Gross profit............................................................. | 3,811 | 2,858 | 9,390 | 9,689 | ||||||||||||
Operating expenses: Selling expenses..................................................... | 24 | 20 | 146 | 79 | ||||||||||||
General and administrative expenses................... | 1,009 | 1,145 | 2,983 | 3,402 | ||||||||||||
Loss on disposal of equipment.............................. | - | 14 | - | 14 | ||||||||||||
Research and development costs.......................... | 713 | 658 | 2,109 | 2,254 | ||||||||||||
Total operating expenses....................................... | 1,746 | 1,837 | 5,238 | 5,749 | ||||||||||||
Operating income................................................... | 2,065 | 1,021 | 4,152 | 3,940 | ||||||||||||
Interest expense...................................................... | (131 | ) | (112 | ) | (389 | ) | (349 | ) | ||||||||
Unrealized gain (loss) on marketable equity investments........................................................ | (177 | ) | (275 | ) | 231 | (427 | ) | |||||||||
Interest and other income...................................... | 11 | - | 235 | 50 | ||||||||||||
Gain on sale of investments.................................. | - | - | 7 | - | ||||||||||||
Income before income taxes................................. | 1,768 | 634 | 4,236 | 3,214 | ||||||||||||
Income tax expense............................................... | (455 | ) | (172 | ) | (968 | ) | (764 | ) | ||||||||
Net income............................................................. | $ | 1,313 | $ | 462 | $ | 3,268 | $ | 2,450 | ||||||||
Basic net income per share: | ||||||||||||||||
Net income......................................................... | $ | 0.37 | $ | 0.13 | $ | 0.91 | $ | 0.67 | ||||||||
Diluted net income per share: | ||||||||||||||||
Net income........................................................ | $ | 0.36 | $ | 0.12 | $ | 0.89 | $ | 0.65 | ||||||||
Weighted average common shares outstanding: | ||||||||||||||||
Basic................................................................... | 3,548 | 3,626 | 3,580 | 3,645 | ||||||||||||
Diluted................................................................ | 3,623 | 3,749 | 3,656 | 3,774 | ||||||||||||
Common shares outstanding................................. | 3,545 | 3,618 | 3,545 | 3,618 | ||||||||||||
CONTACT:
Richard L. Van Kirk, Chief Executive Officer
(949) 769-3200
| Last Trade: | US$48.74 |
| Daily Change: | 2.39 5.16 |
| Daily Volume: | 64,599 |
| Market Cap: | US$158.890M |
September 05, 2024 November 02, 2023 February 02, 2023 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
